We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Highly Sensitive and Specific Test to Enable Early Detection of Colorectal Cancer

By LabMedica International staff writers
Posted on 12 Jun 2025

A highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer could enable treatment at the earliest possible stages of disease development. More...

Tagomics Ltd. (Cambridge, UK) is customizing its Interlace platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer. Tagomics’ Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling that enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Interlace multiomic platform incorporates an innovative approach to epigenetic analysis.

At its heart is a groundbreaking chemoenzymatic method that sorts hypomethylated and hypermethylated biomolecules, providing access to epigenetic biomarkers associated with diseases. In the context of cancer, these markers play a crucial role in enabling earlier diagnosis and pinpointing the tumors tissue of origin. The multiomic platform allows for seamless integration of gene panels or whole genome sequencing, allowing the company to analyze key disease-driving mutations and genomic alterations.

Tagomics’ advanced bioinformatic algorithms grant access to DNA fragmentomic patterns. These markers encompass the length, distribution, and end characteristics of DNA fragments. This offers valuable insights into disease status as fragmentomic features can serve as biomarkers for early disease diagnosis and the identification of tissue of origin. Tagomics will apply Interlace for the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers.

Tagomics will also conduct a pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Following the successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace.

“We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes," said Dr. Robert Neely, CSO and co-founder of Tagomics.

Related Links:
Tagomics Ltd.


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.